New therapeutic options for metastatic malignant insulinomas.
about
Prospective evaluation of biweekly streptozotocin in 19 dogs with insulinoma.Photoactivation of hypericin decreases the viability of RINm5F insulinoma cells through reduction in JNK/ERK phosphorylation and elevation of caspase-9/caspase-3 cleavage and Bax-to-Bcl-2 ratio.Pharmacotherapy of Zollinger-Ellison syndrome.ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.A case of inoperable malignant insulinoma with resistant hypoglycemia who experienced the most significant clinical improvement with everolimus.Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advancesThe treatment of hyperinsulinemic hypoglycaemia in adults: an update.Hepatic arterial infusion combined with systemic chemotherapy induced complete response of metachronous liver metastases after resection of pancreatic insulinoma.ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors."Cherry picking", a multiple non-anatomic liver resection technique, as a promising option for diffuse liver metastases in patients with neuroendocrine tumours.Long-term maintenance of normoglycaemia using everolimus in a patient with disseminated insulinoma and severe hypoglycaemia.Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms.Transformation of nonfunctioning pancreatic tumor into malignant insulinoma after 3 years: an uncommon clinical course of insulinoma.
P2860
Q33407152-B88F9DE8-F795-4BBD-966B-8DC5EC878CB6Q35652360-ED0C41EB-F93A-43C0-A769-E77EA5BD420AQ36632665-9518C743-B8DA-4C86-B914-E5DEF4F1D25BQ36849357-0C04CBC4-6472-4DF3-B91F-AD5D70B52811Q36877057-0B7A1728-98B2-43FD-8B9C-A0E905AAB99DQ37056120-7D35514B-BAA0-45CD-9CCD-09CA7636B5B4Q37125550-DA9F5EC7-6F96-46D8-9FD2-EEEC44C45EE0Q38953515-F37C7961-A8DA-42AA-99B0-540D47C52A93Q40728765-B8AC1B8E-EDD4-4292-AB8E-8F400889B288Q42375203-D29953D3-D294-4741-8801-95D16F115029Q43475328-D94E8AD9-9170-43CD-9787-129701E988B4Q44779570-E7FFB787-5484-47CC-B2AB-9CEAB24A1286Q47724538-5FEBF72A-8F53-463D-8337-0DB1E53F0169Q53435693-2D065E0E-9E06-4C17-B7FC-B7E3188C6C91
P2860
New therapeutic options for metastatic malignant insulinomas.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New therapeutic options for metastatic malignant insulinomas.
@en
New therapeutic options for metastatic malignant insulinomas.
@nl
type
label
New therapeutic options for metastatic malignant insulinomas.
@en
New therapeutic options for metastatic malignant insulinomas.
@nl
prefLabel
New therapeutic options for metastatic malignant insulinomas.
@en
New therapeutic options for metastatic malignant insulinomas.
@nl
P2093
P2860
P1476
New therapeutic options for metastatic malignant insulinomas.
@en
P2093
Dik Kwekkeboom
Ellen van Schaik
Richard A Feelders
P2860
P304
P356
10.1111/J.1365-2265.2011.04145.X
P577
2011-09-01T00:00:00Z